1stOncology™: Cancer Intelligence Service – Page 86 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

On July 30, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported that it has been granted New Zealand Patent No. 785587 titled "WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF" (Press release, BriaCell Therapeutics, JUL 30, 2025, View Source [SID1234655036]). The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell’s precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"We are thrilled that the New Zealand Patent Office recognized the innovative nature of BriaCell’s novel whole cell immunotherapy and its potential therapeutic applications for cancer patients," said Dr. William V. Williams, President and CEO of BriaCell.

The newly granted patent is part of BriaCell’s broader strategy to establish a strong international patent portfolio enabling the global development and commercialization of its immunotherapy platform across multiple cancer indications.

Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

On July 30, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, reported its long-standing collaboration with the University of British Columbia (UBC) and its affiliated Vancouver Prostate Centre (VPC), one of Canada’s leading cancer research institutions (Press release, Rakovina Therapeutics, JUL 30, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-highlights-long-standing-collaboration-with-the-university-of-british-columbia-and-the-vancouver-prostate-centre [SID1234654687]).

Rakovina’s collaboration with the Vancouver Prostate Centre and UBC ensures that compound testing and validation are conducted within one of the world’s most respected cancer facilities. This agreement with UBC enables close collaboration with leading cancer scientists using UBC’s state-of-the-art lab infrastructure, both accelerating and de-risking the translation of scientific discovery.

Furthermore, members of Rakovina’s management team and scientific advisory board hold dual roles within UBC and the Vancouver Prostate Centre, strengthening the connection.

Rakovina’s President and Chief Scientific Officer, Dr. Mads Daugaard, serves as an Associate Professor at UBC and as Senior Research Scientist and Head of Molecular Pathology at the Vancouver Prostate Centre. His dual roles in academia and industry bridge fundamental cancer biology with Rakovina’s proprietary DDR drug discovery programs.

The Company’s AI and medicinal chemistry advisor, Dr. Artem Cherkasov, is a Senior Research Scientist and Head of Precision Cancer Drug Design at the Vancouver Prostate Centre, Professor in the Department of Urologic Sciences at UBC, and Canada Research Chair in Precision Cancer Drug Design. A pioneer in AI-enabled drug discovery, Dr. Cherkasov is the developer of the Deep Docking platform, which drives part of Rakovina’s drug discovery engine and has accelerated the identification of novel DDR inhibitors.

"Our model has been built on strategic alignment with UBC’s research excellence," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "Collaborating with the Vancouver Prostate Centre gives us unique access to the infrastructure, expertise, and collaborative environment needed to rapidly advance next-generation cancer therapies."

Rakovina Therapeutics continues to leverage its deep academic partnerships as it advances multiple oncology programs toward preclinical milestones.

Takeda Quarterly Financial Report For the Quarter Ended June 30, 2025

On July 30, 2025 Takeda reported financial report for the quarter ended June 30, 2025 (Presentation, Takeda, JUL 30, 2025, View Source [SID1234654685]).

Second quarter 2025

On July 30, 2025 GlaxoSmithKline reported Strong Specialty Medicines performance drives sales and core operating profit growth in second quarter of 2025 (Press release, GlaxoSmithKline, JUL 30, 2025, View Source [SID1234654663]).

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

On July 30, 2025 Takeda (TOKYO:4502/NYSE:TAK) reported earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core Operating Profit in line with company expectations for the quarter (Press release, Takeda, JUL 30, 2025, View Source [SID1234654660]). The company expects these impacts to moderate in future quarters.

Takeda also achieved several important milestones in its R&D pipeline, reinforcing its long-term growth trajectory and underscoring its commitment to delivering sustainable value through innovation. Most notably, both Phase 3 studies of oveporexton successfully met all primary and secondary endpoints, demonstrating statistically significant improvements across doses. These results reinforce the potential of oveporexton to transform the standard of care in narcolepsy type 1.

In addition, Takeda received U.S. FDA approval for GAMMAGARD LIQUID ERC and European Commission (EC) approval for ADCETRIS in new indications and presented promising clinical data for rusfertide at the 61st American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting Plenary Session. These developments underscore the strength of Takeda’s late-stage pipeline and its potential to drive future growth.

Takeda chief financial officer, Milano Furuta, commented:
"The impact of VYVANSE generic erosion on Takeda’s FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.

"Our late-stage pipeline continues to advance with the announcement in July of positive results from two pivotal Phase 3 studies for oveporexton in narcolepsy type 1, with both studies meeting all primary and secondary endpoints. These results represent a significant scientific milestone, and we are very excited about the potential for our late-stage pipeline to deliver value to the patients we serve and to position Takeda for sustainable growth."

FINANCIAL HIGHLIGHTS for FY2025 Q1 Ended June 30, 2025

(Billion yen, except percentages and per share amounts)

FY2025 Q1

FY2024 Q1

vs. PRIOR YEAR

(Actual % change)

Revenue

1,106.7

1,208.0

-8.4%

Operating Profit

184.6

166.3

+11.0%

Net Profit

124.2

95.2

+30.4%

EPS (Yen)

+30.8%

Operating Cash Flow

215.4

170.3

+26.5%

Adjusted Free Cash Flow (Non-IFRS)

190.1

23.7

+703.6%

Core (Non-IFRS)

(Billion yen, except percentages and per share amounts)

FY2025 Q1

FY2024 Q1

vs. PRIOR YEAR

(Actual % change)

vs. PRIOR YEAR

(CER % change)

Revenue

1,106.7

1,208.0

-8.4%

-3.7%

Operating Profit

321.8

382.3

-15.8 %

-11.9%

Margin

29.1%

31.6%

-2.6 pp

―

Net Profit

237.0

276.8

-14.4%

-10.3%

EPS (Yen)

151

176

-14.1%

-10.0%

FY2025 Outlook (unchanged from May 2025)

(Billion yen, except percentages and per share amounts)

FY2025 FORECAST

FY2025

MANAGEMENT

GUIDANCE

Core Change at CER

(Non-IFRS)

Revenue

4,530.0

—

Core Revenue (Non-IFRS)

4,530.0

Broadly flat

Operating Profit

475.0

—

Core Operating Profit (Non-IFRS)

1,140.0

Broadly flat

Net Profit

228.0

—

EPS (Yen)

145

—

Core EPS (Yen) (Non-IFRS)

485

Broadly flat

Adjusted Free Cash Flow (Non-IFRS)

750.0-850.0

—

Annual Dividend per Share (Yen)

200

—

Additional Information About Takeda’s FY2025 Q1 Results
For more details about Takeda’s FY2025 Q1 results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2025 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda’s FY2025 Q1 investor presentation (available at View Source).